Free Trial
→ He Called Nvidia at $1.10. Now, He Says THIS Stock Will… (From The Oxford Club) (Ad)tc pixel Free CMRX Stock Alerts

This company has been marked as potentially delisted and may not be actively trading.

Chimerix (CMRX) Financials

Chimerix logo
Compare
Annual Income Statements for Chimerix

Annual Income Statements for Chimerix

This table shows Chimerix's income and expenses over time, based on annual financial data. All values are USD millions unless otherwise specified.

Metric 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024
Period end date 12/31/2014 12/31/2015 12/31/2016 12/31/2017 12/31/2018 12/31/2019 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024
Net Income / (Loss) Attributable to Common Shareholders		 -59 -117 -76 -71 -69 -113 -44 -173 172 -82 -88
Consolidated Net Income / (Loss)		 -59 -117 -76 -71 -69 -113 -44 -173 172 -82 -88
Net Income / (Loss) Continuing Operations		 -59 -117 -76 -71 -69 -113 -44 -173 172 -82 -88
Total Pre-Tax Income 		-59 -117 -76 -71 -69 -113 -44 -173 172 -82 -88
Total Operating Income		 -59 -118 -78 -72 -72 -116 -45 -173 -60 -93 -97
Total Gross Profit		 4.04 11 5.70 4.49 7.22 13 5.37 1.98 33 0.32 0.21
Total Revenue		 4.04 11 5.70 4.49 7.22 13 5.37 1.98 34 0.32 0.21
Operating Revenue		 4.04 11 5.70 4.49 7.22 13 5.37 1.98 34 0.32 0.21
Total Cost of Revenue		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.45 0.00 0.00
Operating Cost of Revenue		 - - - - - - 0.00 0.00 0.45 0.00 0.00
Total Operating Expenses		 63 129 84 77 79 129 50 175 94 93 97
Selling, General & Admin Expense		 18 31 25 27 24 21 14 19 22 25 22
Research & Development Expense		 45 98 59 49 55 107 36 157 72 69 75
Total Other Income / (Expense), net		 -0.45 0.88 1.56 1.12 2.13 3.41 0.99 0.16 233 11 8.18
Interest Expense		 0.45 -0.88 -1.56 -1.12 -2.13 -3.41 -0.99 -0.16 -2.92 -11 -8.18
Other Income / (Expense), net		 - 0.00 0.00 - - - 0.00 0.00 230 0.00 0.00
Income Tax Expense		 - - - - - - 0.00 0.00 0.04 0.00 0.00
Basic Earnings per Share		 ($1.80) ($2.67) ($1.65) ($1.51) ($1.43) ($2.03) ($0.70) ($2.04) $1.97 ($0.93) ($0.99)
Weighted Average Basic Shares Outstanding		 33.00M 43.88M 46.27M 46.96M 48.59M 55.50M 62.18M 84.93M 87.56M 88.60M 89.70M
Diluted Earnings per Share		 ($1.80) ($2.67) ($1.65) ($1.51) ($1.43) ($2.03) ($0.70) ($2.04) $1.94 ($0.93) ($0.99)
Weighted Average Diluted Shares Outstanding		 33.00M 43.88M 46.27M 46.96M 48.59M 55.50M 62.18M 84.93M 88.78M 88.60M 89.70M
Weighted Average Basic & Diluted Shares Outstanding		 33.00M 43.88M 46.27M 46.96M 48.59M 55.50M 62.18M 87.03M 88.27M 89.21M 93.80M

Quarterly Income Statements for Chimerix

This table shows Chimerix's income and expenses over time, based on quarterly financial data. All values are USD millions unless otherwise specified.

Metric Q2 2022 Q3 2022 Q4 2022 Q1 2023 Q2 2023 Q3 2023 Q4 2023 Q1 2024 Q2 2024 Q3 2024 Q4 2024
Period end date 6/30/2022 9/30/2022 12/31/2022 3/31/2023 6/30/2023 9/30/2023 12/31/2023 3/31/2024 6/30/2024 9/30/2024 12/31/2024
Net Income / (Loss) Attributable to Common Shareholders		 -23 241 -21 -21 -19 -24 -18 -22 -21 -23 -23
Consolidated Net Income / (Loss)		 -23 241 -21 -21 -19 -24 -18 -22 -21 -23 -23
Net Income / (Loss) Continuing Operations		 -23 241 -21 -21 -19 -24 -18 -22 -21 -23 -23
Total Pre-Tax Income 		-23 242 -21 -21 -19 -24 -18 -22 -21 -23 -23
Total Operating Income		 -23 12 -24 -24 -21 -27 -21 -24 -23 -25 -25
Total Gross Profit		 0.44 32 0.81 0.28 0.03 0.01 0.00 0.00 0.13 0.03 0.06
Total Revenue		 0.44 33 0.81 0.28 0.03 0.01 0.00 0.00 0.13 0.03 0.06
Operating Revenue		 0.44 33 0.81 0.28 0.03 0.01 0.00 0.00 0.13 0.03 0.06
Total Operating Expenses		 24 21 25 25 21 27 21 24 23 25 25
Selling, General & Admin Expense		 5.84 5.31 5.35 5.68 4.45 9.30 5.17 5.55 4.53 5.17 6.95
Research & Development Expense		 18 15 19 19 17 17 16 19 18 20 18
Total Other Income / (Expense), net		 -0.02 230 2.74 2.85 2.77 2.70 2.65 2.52 2.15 1.91 1.60
Interest Expense		 0.02 -0.20 -2.74 -2.85 -2.77 -2.70 -2.65 -2.52 -2.15 -1.91 -1.60
Basic Earnings per Share		 ($0.27) $2.75 ($0.23) ($0.24) ($0.21) ($0.27) ($0.21) ($0.25) ($0.23) ($0.26) ($0.25)
Weighted Average Basic Shares Outstanding		 87.44M 87.63M 87.56M 88.29M 88.58M 88.62M 88.60M 89.26M 89.63M 89.70M 89.70M
Diluted Earnings per Share		 ($0.27) $2.75 ($0.26) ($0.24) ($0.21) ($0.27) ($0.21) ($0.25) ($0.23) ($0.26) ($0.25)
Weighted Average Diluted Shares Outstanding		 87.44M 87.81M 88.78M 88.29M 88.58M 88.62M 88.60M 89.26M 89.63M 89.70M 89.70M
Weighted Average Basic & Diluted Shares Outstanding		 87.62M 88.05M 88.27M 88.58M 88.58M 88.89M 89.21M 89.63M 89.64M 89.94M 93.80M

Annual Cash Flow Statements for Chimerix

This table details how cash moves in and out of Chimerix's business through operations, investing, and financing, using annual figures. All values are USD millions unless otherwise specified.

Metric 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024
Period end date 12/31/2014 12/31/2015 12/31/2016 12/31/2017 12/31/2018 12/31/2019 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024
Net Change in Cash & Equivalents		 18 -108 31 -33 63 -64 30 -32 10 1.82 3.39
Net Cash From Operating Activities		 -47 -100 -64 -50 -54 -75 -36 -100 -47 -69 -75
Net Cash From Continuing Operating Activities		 -47 -100 -64 -50 -54 -75 -36 -100 -47 -69 -75
Net Income / (Loss) Continuing Operations		 -59 -117 -76 -71 -69 -113 -44 -173 172 -82 -88
Consolidated Net Income / (Loss)		 -59 -117 -76 -71 -69 -113 -44 -173 172 -82 -88
Depreciation Expense		 0.28 0.66 1.06 1.09 0.86 0.56 0.40 0.17 0.10 0.09 0.09
Amortization Expense		 1.32 1.69 1.22 -0.01 -0.85 -1.92 -0.20 1.15 -1.32 -6.96 -3.47
Non-Cash Adjustments To Reconcile Net Income		 4.41 13 16 17 14 45 5.55 70 -214 17 9.47
Changes in Operating Assets and Liabilities, net		 6.22 2.36 -5.93 2.49 1.94 -5.97 1.73 2.29 -3.42 2.42 7.44
Net Cash From Investing Activities		 -160 -169 94 16 105 11 65 -44 70 71 71
Net Cash From Continuing Investing Activities		 -160 -169 94 16 105 11 65 -44 70 71 71
Purchase of Property, Plant & Equipment		 -1.02 -2.39 -0.84 -0.15 -0.18 -0.16 -0.06 -0.21 -0.07 -0.09 -0.29
Purchase of Investments		 -211 -295 -103 -163 -132 -168 -74 -115 -241 -129 -131
Sale of Property, Plant & Equipment		 - - - - 0.00 0.00 0.01 0.00 0.00 0.01 0.00
Divestitures		 - - - - - - 0.00 0.00 234 0.00 0.00
Sale and/or Maturity of Investments		 52 128 198 179 237 178 139 71 77 199 203
Net Cash From Financing Activities		 225 161 0.61 0.78 11 0.35 1.41 112 -13 0.31 7.05
Net Cash From Continuing Financing Activities		 225 161 0.61 0.78 11 0.35 1.41 112 -13 0.31 7.05
Repayment of Debt		 -5.70 -4.69 - - - - 0.00 0.00 -14 -0.16 -0.40
Issuance of Common Equity		 226 163 0.44 0.71 11 0.33 0.43 109 0.86 0.47 7.44
Other Financing Activities, net		 4.60 3.11 0.17 0.12 0.12 0.04 0.99 3.83 0.61 0.00 0.01

Quarterly Cash Flow Statements for Chimerix

This table details how cash moves in and out of Chimerix's business through operations, investing, and financing, using quarterly figures. All values are USD millions unless otherwise specified.

Metric Q2 2022 Q3 2022 Q4 2022 Q1 2023 Q2 2023 Q3 2023 Q4 2023 Q1 2024 Q2 2024 Q3 2024 Q4 2024
Period end date 6/30/2022 9/30/2022 12/31/2022 3/31/2023 6/30/2023 9/30/2023 12/31/2023 3/31/2024 6/30/2024 9/30/2024 12/31/2024
Net Change in Cash & Equivalents		 -3.87 246 -248 -9.89 4.15 -5.98 14 -8.64 -3.37 7.99 7.40
Net Cash From Operating Activities		 -11 7.13 -20 -22 -14 -18 -15 -18 -18 -21 -19
Net Cash From Continuing Operating Activities		 -11 7.13 -20 -22 -14 -18 -15 -17 -18 -21 -19
Net Income / (Loss) Continuing Operations		 -23 241 -21 -21 -19 -24 -18 -22 -21 -23 -23
Consolidated Net Income / (Loss)		 -23 241 -21 -21 -19 -24 -18 -22 -21 -23 -23
Depreciation Expense		 0.02 0.03 0.03 0.02 0.02 0.02 0.02 0.02 0.02 0.02 0.03
Amortization Expense		 0.07 0.06 -1.60 -2.05 -1.86 -1.61 -1.44 -1.12 -1.13 -0.79 -0.44
Non-Cash Adjustments To Reconcile Net Income		 3.59 -226 4.17 4.36 2.96 7.88 2.25 2.75 2.19 2.38 2.14
Changes in Operating Assets and Liabilities, net		 9.22 -8.47 -1.62 -3.19 3.11 -0.24 2.74 2.72 1.89 0.75 2.07
Net Cash From Investing Activities		 6.70 238 -228 12 19 12 28 8.68 14 28 20
Net Cash From Continuing Investing Activities		 6.70 238 -228 12 19 12 28 8.68 14 28 20
Purchase of Property, Plant & Equipment		 - -0.07 0.00 -0.06 -0.01 -0.02 - -0.03 -0.07 -0.03 -0.16
Purchase of Investments		 - -6.05 -230 -6.80 -39 -51 -32 -41 -24 -30 -36
Sale and/or Maturity of Investments		 6.70 10 1.35 19 57 63 60 50 39 58 56
Net Cash From Financing Activities		 -0.01 0.78 -0.03 0.20 -0.03 0.08 0.06 0.21 -0.04 0.18 6.71
Net Cash From Continuing Financing Activities		 -0.01 0.78 -0.03 0.20 -0.03 0.08 0.06 0.21 -0.04 0.18 6.71
Repayment of Debt		 - - -0.19 -0.16 -0.03 -0.03 0.06 -0.17 -0.04 -0.04 -0.14
Issuance of Common Equity		 - 0.30 - 0.36 - 0.11 - 0.38 - 0.22 6.84
Other Financing Activities, net		 - 0.51 - - - - - - - - 0.01

Annual Balance Sheets for Chimerix

This table presents Chimerix's assets and liabilities at the end of each period, using annual balance sheet data. All values are USD millions unless otherwise specified.

Metric 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024
Period end date 12/31/2014 12/31/2015 12/31/2016 12/31/2017 12/31/2018 12/31/2019 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024
Total Assets		 292 356 287 235 191 119 85 101 279 213 146
Total Current Assets		 237 229 236 157 189 118 82 96 228 189 136
Cash & Equivalents		 128 21 51 19 81 17 47 15 26 28 31
Short-Term Investments		 106 200 181 133 105 97 32 73 191 155 101
Accounts Receivable		 0.11 2.43 1.60 1.68 0.33 1.23 0.34 0.00 1.04 0.00 0.06
Prepaid Expenses		 2.78 6.07 2.85 3.33 2.60 3.39 2.36 4.68 9.76 6.27 4.25
Plant, Property, & Equipment, net		 1.31 3.05 2.84 1.89 1.21 0.54 0.21 0.25 0.23 0.22 0.42
Total Noncurrent Assets		 53 124 47 77 0.05 0.74 2.85 4.48 51 23 9.64
Long-Term Investments		 53 124 47 77 - - 0.00 2.02 49 22 8.48
Other Noncurrent Operating Assets		 0.14 0.07 0.06 0.07 0.05 0.74 2.85 2.46 2.35 1.78 1.17
Total Liabilities & Shareholders' Equity		 292 356 287 235 191 119 85 101 279 213 146
Total Liabilities		 17 21 11 13 13 9.42 11 32 22 20 24
Total Current Liabilities		 17 20 10 13 13 9.23 8.53 30 20 18 24
Accounts Payable		 5.94 10 3.89 3.81 4.69 2.40 1.28 2.79 3.03 2.85 3.94
Accrued Expenses		 6.83 9.72 6.22 9.38 8.28 6.83 7.25 13 17 16 20
Total Noncurrent Liabilities		 0.18 0.35 0.44 0.22 0.14 0.20 2.81 2.39 2.07 1.30 0.46
Other Noncurrent Operating Liabilities		 0.18 - 0.44 0.22 0.14 0.20 2.81 2.39 2.07 1.30 0.46
Total Equity & Noncontrolling Interests		 275 335 276 222 178 110 73 68 257 193 122
Total Preferred & Common Equity		 275 335 276 222 178 110 73 68 257 193 122
Preferred Stock		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Common Equity		 275 335 276 222 178 110 73 68 257 193 122
Common Stock		 497 676 692 710 734 779 786 954 971 989 1,006
Retained Earnings		 -222 -339 -416 -487 -556 -669 -712 -886 -713 -796 -884
Accumulated Other Comprehensive Income / (Loss)		 0.04 -0.76 -0.44 -0.96 -0.09 0.04 0.00 -0.02 -0.34 0.01 0.02

Quarterly Balance Sheets for Chimerix

This table presents Chimerix's assets and liabilities at the end of each period, using quarterly balance sheet data. All values are USD millions unless otherwise specified.

Metric Q2 2022 Q3 2022 Q1 2023 Q2 2023 Q3 2023 Q1 2024 Q2 2024 Q3 2024
Period end date 6/30/2022 9/30/2022 3/31/2023 6/30/2023 9/30/2023 3/31/2024 6/30/2024 9/30/2024
Total Assets		 54 294 259 241 225 194 179 159
Total Current Assets		 51 291 225 212 201 163 153 141
Cash & Equivalents		 28 274 16 20 14 19 16 24
Short-Term Investments		 15 10 199 186 180 140 133 113
Accounts Receivable		 - 0.47 0.67 0.03 0.01 0.00 0.13 0.16
Prepaid Expenses		 3.85 6.02 9.33 5.74 6.14 4.00 5.16 4.52
Plant, Property, & Equipment, net		 0.21 0.25 0.27 0.26 0.25 0.26 0.28 0.28
Total Noncurrent Assets		 2.59 2.51 34 29 24 31 25 17
Long-Term Investments		 0.00 0.00 31 27 23 29 23 16
Other Noncurrent Operating Assets		 2.59 2.51 2.19 2.05 1.90 1.61 1.47 1.28
Total Liabilities & Shareholders' Equity		 54 294 259 241 225 194 179 159
Total Liabilities		 26 20 18 17 17 20 23 23
Total Current Liabilities		 23 18 16 15 16 19 22 22
Accounts Payable		 1.74 3.28 2.85 1.82 2.50 3.82 4.16 5.34
Accrued Expenses		 17 14 14 14 13 15 18 17
Total Noncurrent Liabilities		 2.36 2.22 1.79 1.63 1.47 1.01 0.83 0.64
Other Noncurrent Operating Liabilities		 2.11 1.97 1.79 1.63 1.47 1.01 0.83 0.64
Total Equity & Noncontrolling Interests		 28 274 240 224 208 174 156 136
Total Preferred & Common Equity		 28 274 240 224 208 174 156 136
Preferred Stock		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Common Equity		 28 274 240 224 208 174 156 136
Common Stock		 962 966 975 978 986 992 994 996
Retained Earnings		 -934 -692 -735 -753 -777 -817 -838 -861
Accumulated Other Comprehensive Income / (Loss)		 -0.07 -0.04 -0.23 -0.81 -0.63 -0.18 -0.21 0.26

Annual Metrics And Ratios for Chimerix

This table displays calculated financial ratios and metrics derived from Chimerix's official financial filings.

Metric 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024
Period end date 12/31/2014 12/31/2015 12/31/2016 12/31/2017 12/31/2018 12/31/2019 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024
Growth Metrics		 - - - - - - - - - - -
Revenue Growth		 -7.55% 166.39% -47.02% -21.19% 60.57% 73.49% -57.09% -63.16% 1,609.15% -99.04% -34.57%
EBITDA Growth		 -65.99% -102.42% 34.72% 6.15% -0.82% -63.89% 62.23% -288.30% 197.66% -159.46% -0.02%
EBIT Growth		 -67.19% -100.88% 34.08% 7.50% 0.69% -61.98% 61.62% -289.52% 197.63% -154.98% -3.76%
NOPAT Growth		 -105.69% -100.88% 34.08% 7.50% 0.69% -61.98% 61.62% -289.52% 50.26% -7.90% -3.76%
Net Income Growth		 -62.74% -97.89% 34.92% 7.08% 2.13% -62.04% 61.34% -298.04% 199.38% -147.68% -7.66%
EPS Growth		 50.68% -48.33% 38.20% 8.48% 5.30% -41.96% 65.52% -191.43% 195.10% -147.94% -6.45%
Operating Cash Flow Growth		 -84.19% -111.80% 36.00% 21.45% -7.18% -39.94% 52.07% -177.29% 53.10% -47.41% -8.52%
Free Cash Flow Firm Growth		 7.11% -141.45% 26.92% 21.64% -0.86% -81.77% 66.40% -308.37% 50.01% -5.69% 3.45%
Invested Capital Growth		 -448.85% -3.46% 64.06% -101.03% -38.58% 60.53% -58.56% -45.67% -11.87% -25.93% -60.86%
Revenue Q/Q Growth		 7.36% 22.18% -16.54% -2.94% 71.97% 17.93% -51.25% -35.18% 2.32% -71.43% 33.33%
EBITDA Q/Q Growth		 -25.76% -18.29% 23.07% -5.34% 3.85% 8.96% -20.33% -19.24% 322.46% 3.07% -2.91%
EBIT Q/Q Growth		 -26.27% -17.95% 22.67% -4.82% 4.36% 9.05% -21.52% -19.07% 322.44% 3.13% -4.03%
NOPAT Q/Q Growth		 -26.27% -17.95% 22.67% -4.82% 4.36% 9.05% -21.52% -19.07% 20.67% 3.13% -4.03%
Net Income Q/Q Growth		 -25.56% -17.63% 23.05% -6.42% 5.81% 9.23% -23.12% -19.13% 12.07% 3.30% -5.73%
EPS Q/Q Growth		 -109.55% -12.18% 23.96% -5.59% 7.14% 9.78% -20.69% -12.09% 8.38% 5.10% -4.21%
Operating Cash Flow Q/Q Growth		 -27.27% -19.18% 26.68% -5.09% 6.64% 6.04% -18.30% -33.33% 23.05% 7.25% -6.66%
Free Cash Flow Firm Q/Q Growth		 -5.69% -23.18% 22.86% -2.60% 8.16% 3.01% -12.73% -18.21% 17.12% 8.99% -6.33%
Invested Capital Q/Q Growth		 -32.98% 8.09% -50.85% -51.91% -86.81% 26.10% -21.54% -35.46% 12.71% -31.97% -10.74%
Profitability Metrics		 - - - - - - - - - - -
Gross Margin		 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 98.68% 100.00% 100.00%
EBITDA Margin		 -1,417.33% -1,077.01% -1,327.01% -1,580.24% -992.20% -937.27% -824.98% -8,695.60% 496.86% -30,842.59% -47,143.87%
Operating Margin		 -1,457.08% -1,098.78% -1,367.10% -1,604.41% -992.31% -926.46% -828.67% -8,762.00% -178.53% -28,723.77% -45,550.47%
EBIT Margin		 -1,457.08% -1,098.78% -1,367.10% -1,604.41% -992.31% -926.46% -828.67% -8,762.00% 500.48% -28,723.77% -45,550.47%
Profit (Net Income) Margin		 -1,468.12% -1,090.62% -1,339.71% -1,579.53% -962.78% -899.24% -810.16% -8,753.71% 509.01% -25,337.96% -41,691.98%
Tax Burden Percent		 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 99.98% 100.00% 100.00%
Interest Burden Percent		 100.76% 99.26% 98.00% 98.45% 97.02% 97.06% 97.77% 99.91% 101.72% 88.21% 91.53%
Effective Tax Rate		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.02% 0.00% 0.00%
Return on Invested Capital (ROIC)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
ROIC Less NNEP Spread (ROIC-NNEP)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Net Nonoperating Assets (RNNOA)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Equity (ROE)		 -31.79% -38.48% -24.98% -28.51% -34.79% -78.30% -47.48% -244.64% 105.91% -36.50% -56.17%
Cash Return on Invested Capital (CROIC)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Operating Return on Assets (OROA)		 -29.05% -36.50% -24.26% -27.63% -33.62% -74.81% -43.62% -187.19% 89.12% -37.82% -53.83%
Return on Assets (ROA)		 -29.27% -36.23% -23.77% -27.20% -32.62% -72.61% -42.65% -187.02% 90.64% -33.36% -49.27%
Return on Common Equity (ROCE)		 -31.79% -38.48% -24.98% -28.51% -34.79% -78.30% -47.48% -244.64% 105.91% -36.50% -56.17%
Return on Equity Simple (ROE_SIMPLE)		 -21.60% -34.99% -27.66% -32.00% -39.12% -102.39% -59.31% -253.82% 67.03% -42.53% -72.64%
Net Operating Profit after Tax (NOPAT)		 -41 -83 -55 -50 -50 -81 -31 -121 -60 -65 -68
NOPAT Margin		 -1,019.96% -769.15% -956.97% -1,123.08% -694.62% -648.52% -580.07% -6,133.40% -178.49% -20,106.64% -31,885.33%
Net Nonoperating Expense Percent (NNEP)		 -9.45% -11.02% -7.00% -8.08% -9.33% -20.92% -12.85% -66.76% 135.85% -7.21% -12.07%
Return On Investment Capital (ROIC_SIMPLE)		 - - - - - - - - -23.50% -33.75% -55.55%
Cost of Revenue to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 1.32% 0.00% 0.00%
SG&A Expenses to Revenue		 433.84% 290.80% 438.57% 604.09% 326.80% 169.10% 254.21% 943.51% 65.43% 7,592.90% 10,474.06%
R&D to Revenue		 1,123.24% 907.98% 1,028.53% 1,100.31% 765.51% 857.36% 674.46% 7,918.49% 211.78% 21,230.86% 35,176.42%
Operating Expenses to Revenue		 1,557.08% 1,198.78% 1,467.10% 1,704.41% 1,092.31% 1,026.46% 928.67% 8,862.00% 277.21% 28,823.77% 45,650.47%
Earnings before Interest and Taxes (EBIT)		 -59 -118 -78 -72 -72 -116 -45 -173 169 -93 -97
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)		 -57 -116 -76 -71 -72 -117 -44 -172 168 -100 -100
Valuation Ratios		 - - - - - - - - - - -
Price to Book Value (P/BV)		 5.35 1.23 0.77 0.98 0.73 1.13 4.12 8.18 0.64 0.44 2.57
Price to Tangible Book Value (P/TBV)		 5.35 1.23 0.77 0.98 0.73 1.13 4.12 8.18 0.64 0.44 2.57
Price to Revenue (P/Rev)		 363.49 38.38 37.36 48.55 18.07 9.95 56.31 282.23 4.84 264.07 1,476.31
Price to Earnings (P/E)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.95 0.00 0.00
Dividend Yield		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings Yield		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 105.13% 0.00% 0.00%
Enterprise Value to Invested Capital (EV/IC)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Revenue (EV/Rev)		 293.38 6.38 0.00 0.00 0.00 0.89 41.62 243.63 0.00 0.00 815.37
Enterprise Value to EBITDA (EV/EBITDA)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to EBIT (EV/EBIT)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to NOPAT (EV/NOPAT)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Operating Cash Flow (EV/OCF)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Free Cash Flow (EV/FCFF)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Leverage & Solvency		 - - - - - - - - - - -
Debt to Equity		 0.02 0.00 0.00 0.00 0.00 0.00 0.00 0.21 0.00 0.00 0.00
Long-Term Debt to Equity		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Financial Leverage		 -1.03 -1.03 -1.02 -1.02 -1.04 -1.04 -1.05 -1.10 -1.05 -1.05 -1.10
Leverage Ratio		 1.09 1.06 1.05 1.05 1.07 1.08 1.11 1.31 1.17 1.09 1.14
Compound Leverage Factor		 1.09 1.05 1.03 1.03 1.03 1.05 1.09 1.31 1.19 0.96 1.04
Debt to Total Capital		 1.54% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 17.02% 0.00% 0.00% 0.00%
Short-Term Debt to Total Capital		 1.54% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 17.02% 0.00% 0.00% 0.00%
Long-Term Debt to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Preferred Equity to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Noncontrolling Interests to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Common Equity to Total Capital		 98.46% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 82.98% 100.00% 100.00% 100.00%
Debt to EBITDA		 -0.08 0.00 0.00 0.00 0.00 0.00 0.00 -0.08 0.00 0.00 0.00
Net Debt to EBITDA		 4.95 0.00 0.00 0.00 0.00 0.00 0.00 0.44 0.00 0.00 0.00
Long-Term Debt to EBITDA		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Debt to NOPAT		 -0.10 0.00 0.00 0.00 0.00 0.00 0.00 -0.12 0.00 0.00 0.00
Net Debt to NOPAT		 6.87 0.00 0.00 0.00 0.00 0.00 0.00 0.63 0.00 0.00 0.00
Long-Term Debt to NOPAT		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Altman Z-Score		 50.29 10.37 10.16 6.60 1.79 -1.92 3.59 -6.84 3.81 -3.11 -2.02
Noncontrolling Interest Sharing Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Liquidity Ratios		 - - - - - - - - - - -
Current Ratio		 13.91 11.34 23.40 11.86 14.61 12.80 9.57 3.20 11.18 10.25 5.70
Quick Ratio		 13.75 11.04 23.12 11.61 14.41 12.43 9.29 2.96 10.70 9.91 5.52
Cash Flow Metrics		 - - - - - - - - - - -
Free Cash Flow to Firm (FCFF)		 -34 -82 -60 -47 -48 -87 -29 -119 -59 -63 -61
Operating Cash Flow to CapEx		 -4,624.46% -4,166.65% -7,587.99% -33,195.36% -29,682.32% -47,582.91% -75,079.17% -48,275.36% -66,009.86% -85,293.83% -26,124.39%
Free Cash Flow to Firm to Interest Expense		 -76.59 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Operating Cash Flow to Interest Expense		 -105.55 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Operating Cash Flow Less CapEx to Interest Expense		 -107.84 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Efficiency Ratios		 - - - - - - - - - - -
Asset Turnover		 0.02 0.03 0.02 0.02 0.03 0.08 0.05 0.02 0.18 0.00 0.00
Accounts Receivable Turnover		 22.82 8.48 2.83 2.74 7.17 16.02 6.83 0.00 0.00 0.62 6.95
Inventory Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Fixed Asset Turnover		 4.90 4.94 1.94 1.90 4.65 14.31 14.25 8.48 140.93 1.44 0.66
Accounts Payable Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.15 0.00 0.00
Days Sales Outstanding (DSO)		 15.99 43.04 129.02 133.24 50.89 22.79 53.44 0.00 0.00 588.06 52.51
Days Inventory Outstanding (DIO)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Days Payable Outstanding (DPO)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 2,376.99 0.00 0.00
Cash Conversion Cycle (CCC)		 15.99 43.04 129.02 133.24 50.89 22.79 53.44 0.00 -2,376.99 588.06 52.51
Capital & Investment Metrics		 - - - - - - - - - - -
Invested Capital		 -8.62 -8.92 -3.20 -6.44 -8.93 -3.52 -5.59 -8.14 -9.10 -11 -18
Invested Capital Turnover		 -0.79 -1.23 -0.94 -0.93 -0.94 -2.01 -1.18 -0.29 -3.92 -0.03 -0.01
Increase / (Decrease) in Invested Capital		 -7.05 -0.30 5.71 -3.24 -2.49 5.40 -2.06 -2.55 -0.97 -2.36 -6.98
Enterprise Value (EV)		 1,185 69 -66 -10 -56 11 224 482 -102 -119 173
Market Capitalization		 1,469 413 213 218 130 125 303 559 164 86 313
Book Value per Share		 $7.53 $7.27 $5.96 $4.71 $3.50 $1.79 $1.17 $0.79 $2.92 $2.17 $1.35
Tangible Book Value per Share		 $7.53 $7.27 $5.96 $4.71 $3.50 $1.79 $1.17 $0.79 $2.92 $2.17 $1.35
Total Capital		 279 335 276 222 178 110 73 82 257 193 122
Total Debt		 4.30 0.00 0.00 0.00 0.00 0.00 0.00 14 0.00 0.00 0.00
Total Long-Term Debt		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Net Debt		 -283 -344 -279 -228 -187 -113 -79 -76 -266 -204 -140
Capital Expenditures (CapEx)		 1.02 2.39 0.84 0.15 0.18 0.16 0.05 0.21 0.07 0.08 0.29
Debt-free, Cash-free Net Working Capital (DFCFNWC)		 -9.89 -12 -5.66 -8.18 -10 -4.61 -5.84 -8.46 -9.61 -12 -20
Debt-free Net Working Capital (DFNWC)		 225 209 226 143 176 109 73 80 208 171 112
Net Working Capital (NWC)		 220 209 226 143 176 109 73 66 208 171 112
Net Nonoperating Expense (NNE)		 18 35 22 21 19 31 12 52 -233 17 21
Net Nonoperating Obligations (NNO)		 -283 -344 -279 -228 -187 -113 -79 -76 -266 -204 -140
Total Depreciation and Amortization (D&A)		 1.61 2.34 2.29 1.09 0.01 -1.35 0.20 1.31 -1.23 -6.87 -3.38
Debt-free, Cash-free Net Working Capital to Revenue		 -244.80% -108.49% -99.28% -182.09% -139.11% -36.82% -108.66% -427.39% -28.41% -3,755.56% -9,227.83%
Debt-free Net Working Capital to Revenue		 5,561.53% 1,938.84% 3,969.84% 3,189.52% 2,445.84% 869.60% 1,361.22% 4,037.85% 614.13% 52,675.00% 52,867.92%
Net Working Capital to Revenue		 5,455.20% 1,938.84% 3,969.84% 3,189.52% 2,445.84% 869.60% 1,361.22% 3,330.42% 614.13% 52,675.00% 52,867.92%
Earnings Adjustments		 - - - - - - - - - - -
Adjusted Basic Earnings per Share		 ($1.80) ($2.67) ($1.65) ($1.51) ($1.43) ($2.03) ($0.70) ($2.04) $1.97 ($0.93) ($0.99)
Adjusted Weighted Average Basic Shares Outstanding		 41.09M 46.18M 46.56M 47.65M 50.90M 61.74M 85.68M 84.93M 87.56M 88.60M 89.70M
Adjusted Diluted Earnings per Share		 ($1.80) ($2.67) ($1.65) ($1.51) ($1.43) ($2.03) ($0.70) ($2.04) $1.94 ($0.93) ($0.99)
Adjusted Weighted Average Diluted Shares Outstanding		 41.09M 46.18M 46.56M 47.65M 50.90M 61.74M 85.68M 84.93M 88.78M 88.60M 89.70M
Adjusted Basic & Diluted Earnings per Share		 ($1.80) ($2.67) ($1.65) ($1.51) ($1.43) ($2.03) ($0.70) $0.00 $0.00 $0.00 $0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding		 33.00M 43.88M 46.27M 46.96M 48.59M 55.50M 62.18M 87.03M 88.27M 89.21M 93.80M
Normalized Net Operating Profit after Tax (NOPAT)		 -41 -83 -55 -50 -50 -81 -31 -121 -60 -65 -68
Normalized NOPAT Margin		 -1,019.96% -769.15% -956.97% -1,123.08% -694.62% -648.52% -580.07% -6,133.40% -178.49% -20,106.64% -31,885.33%
Pre Tax Income Margin		 -1,468.12% -1,090.62% -1,339.71% -1,579.53% -962.78% -899.24% -810.16% -8,753.71% 509.11% -25,337.96% -41,691.98%
Debt Service Ratios		 - - - - - - - - - - -
EBIT to Interest Expense		 -131.99 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
NOPAT to Interest Expense		 -92.39 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
EBIT Less CapEx to Interest Expense		 -134.27 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
NOPAT Less CapEx to Interest Expense		 -94.67 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Payout Ratios		 - - - - - - - - - - -
Dividend Payout Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Augmented Payout Ratio		 0.00% 0.00% 0.00% -0.08% -0.58% -0.02% 0.00% 0.00% 0.00% 0.00% 0.00%

Quarterly Metrics And Ratios for Chimerix

This table displays calculated financial ratios and metrics derived from Chimerix's official financial filings.

Metric Q2 2022 Q3 2022 Q4 2022 Q1 2023 Q2 2023 Q3 2023 Q4 2023 Q1 2024 Q2 2024 Q3 2024 Q4 2024
Period end date 6/30/2022 9/30/2022 12/31/2022 3/31/2023 6/30/2023 9/30/2023 12/31/2023 3/31/2024 6/30/2024 9/30/2024 12/31/2024
Growth Metrics		 - - - - - - - - - - -
Revenue Growth		 12.53% 30,325.23% 1,669.57% 1,786.67% -94.09% -99.97% -99.51% -100.00% 396.15% 136.36% 1,325.00%
EBITDA Growth		 -35.33% 1,419.55% 35.43% -6.70% 0.70% -111.71% 12.47% 2.89% -3.23% 9.60% -12.33%
EBIT Growth		 -31.61% 1,397.40% 39.76% 2.23% 8.95% -111.06% 12.61% -0.71% -6.95% 7.10% -17.98%
NOPAT Growth		 -31.61% 189.39% 39.76% 2.23% 8.95% -260.52% 12.61% -0.71% -6.95% 7.10% -17.98%
Net Income Growth		 -32.12% 1,400.44% 46.93% 13.71% 20.85% -109.94% 13.35% -2.33% -11.35% 4.62% -26.39%
EPS Growth		 -28.57% 1,409.52% 36.59% 14.29% 22.22% -109.82% 19.23% -4.17% -9.52% 3.70% -19.05%
Operating Cash Flow Growth		 17.00% 146.62% 41.25% 5.21% -35.81% -351.59% 27.02% 21.18% -23.30% -14.36% -32.08%
Free Cash Flow Firm Growth		 7.39% 238.34% 37.49% 2.17% -151.43% -227.18% 22.27% 46.87% 56.51% 54.02% 16.36%
Invested Capital Growth		 -127.79% -73.60% -11.87% -8.12% 39.08% 16.71% -25.93% -143.95% -78.63% -91.70% -60.86%
Revenue Q/Q Growth		 2,833.33% 7,298.86% -97.50% -65.23% -90.81% -57.69% -63.64% -100.00% 0.00% -79.85% 119.23%
EBITDA Q/Q Growth		 5.07% 1,133.74% -110.52% -3.37% 11.65% -21.93% 21.40% -15.15% 6.08% -6.78% 2.34%
EBIT Q/Q Growth		 5.35% 1,129.20% -109.87% -1.70% 11.85% -25.02% 22.03% -17.20% 6.39% -8.59% 0.97%
NOPAT Q/Q Growth		 5.35% 170.91% -243.23% -1.70% 11.85% -25.02% 22.03% -17.20% 6.39% -8.59% 0.97%
Net Income Q/Q Growth		 5.24% 1,128.47% -108.68% -1.97% 13.08% -29.12% 24.29% -20.42% 5.41% -10.61% -0.33%
EPS Q/Q Growth		 3.57% 1,118.52% -109.45% 7.69% 12.50% -28.57% 22.22% -19.05% 8.00% -13.04% 3.85%
Operating Cash Flow Q/Q Growth		 54.96% 167.50% -380.42% -11.19% 35.47% -25.04% 18.65% -20.09% -0.94% -15.98% 6.05%
Free Cash Flow Firm Q/Q Growth		 51.35% 295.49% -197.78% -5.19% -25.03% 1.12% 40.23% 28.10% -2.34% -4.54% -8.74%
Invested Capital Q/Q Growth		 -174.17% 28.64% 12.71% 36.69% -54.47% 2.43% -31.97% -22.65% -13.11% -4.71% -10.74%
Profitability Metrics		 - - - - - - - - - - -
Gross Margin		 100.00% 98.98% 100.00% 100.00% 100.00% 100.00% 100.00% 0.00% 100.00% 100.00% 100.00%
EBITDA Margin		 -5,307.27% 741.51% -3,119.16% -9,274.20% -89,184.62% -257,027.27% -555,575.00% 0.00% -18,555.81% -98,303.85% -43,792.98%
Operating Margin		 -5,328.86% 35.77% -2,925.55% -8,557.60% -82,107.69% -242,627.27% -520,250.00% 0.00% -17,699.22% -95,357.69% -43,073.68%
EBIT Margin		 -5,328.86% 741.26% -2,925.55% -8,557.60% -82,107.69% -242,627.27% -520,250.00% 0.00% -17,699.22% -95,357.69% -43,073.68%
Profit (Net Income) Margin		 -5,333.64% 741.40% -2,574.94% -7,551.94% -71,446.15% -218,054.55% -454,025.00% 0.00% -16,034.88% -87,996.15% -40,270.18%
Tax Burden Percent		 100.00% 99.94% 99.44% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00%
Interest Burden Percent		 100.09% 100.08% 88.51% 88.25% 87.02% 89.87% 87.27% 89.66% 90.60% 92.28% 93.49%
Effective Tax Rate		 0.00% 0.06% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Invested Capital (ROIC)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
ROIC Less NNEP Spread (ROIC-NNEP)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Net Nonoperating Assets (RNNOA)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Equity (ROE)		 -144.54% 81.17% 105.91% 121.87% 143.19% -35.21% -36.50% -39.86% -44.62% -48.59% -56.17%
Cash Return on Invested Capital (CROIC)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Operating Return on Assets (OROA)		 -32.35% 114.69% -520.97% -1,800.63% -18,769.67% -1,059.94% -685.05% 0.00% -12.15% -78.98% -50.90%
Return on Assets (ROA)		 -32.38% 114.71% -458.54% -1,589.02% -16,332.46% -952.59% -597.84% 0.00% -11.01% -72.88% -47.59%
Return on Common Equity (ROCE)		 -144.54% 81.17% 105.91% 121.87% 143.19% -35.21% -36.50% -39.86% -44.62% -48.59% -56.17%
Return on Equity Simple (ROE_SIMPLE)		 -380.60% 56.08% 0.00% 73.06% 80.52% -40.76% 0.00% -47.44% -54.44% -61.57% 0.00%
Net Operating Profit after Tax (NOPAT)		 -16 12 -17 -17 -15 -19 -15 -17 -16 -17 -17
NOPAT Margin		 -3,730.20% 35.75% -2,047.89% -5,990.32% -57,475.38% -169,839.09% -364,175.00% 0.00% -12,389.46% -66,750.38% -30,151.58%
Net Nonoperating Expense Percent (NNEP)		 -8.39% 116.32% -2.51% -2.95% -2.64% -2.12% -1.53% -2.21% -2.33% -2.99% -3.35%
Return On Investment Capital (ROIC_SIMPLE)		 - - -6.49% - - - -7.55% - - - -14.12%
Cost of Revenue to Revenue		 0.00% 1.02% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
SG&A Expenses to Revenue		 1,327.27% 16.32% 656.88% 2,006.71% 17,107.69% 84,581.82% 129,250.00% 0.00% 3,513.95% 19,896.15% 12,198.25%
R&D to Revenue		 4,101.59% 46.88% 2,368.67% 6,650.88% 65,100.00% 158,145.45% 391,100.00% 0.00% 14,285.27% 75,561.54% 30,975.44%
Operating Expenses to Revenue		 5,428.86% 63.20% 3,025.55% 8,657.60% 82,207.69% 242,727.27% 520,350.00% 0.00% 17,799.22% 95,457.69% 43,173.68%
Earnings before Interest and Taxes (EBIT)		 -23 241 -24 -24 -21 -27 -21 -24 -23 -25 -25
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)		 -23 241 -25 -26 -23 -28 -22 -25 -24 -26 -25
Valuation Ratios		 - - - - - - - - - - -
Price to Book Value (P/BV)		 6.51 0.62 0.64 0.46 0.48 0.41 0.44 0.54 0.50 0.61 2.57
Price to Tangible Book Value (P/TBV)		 6.51 0.62 0.64 0.46 0.48 0.41 0.44 0.54 0.50 0.61 2.57
Price to Revenue (P/Rev)		 299.12 5.12 4.84 3.26 3.18 74.98 264.07 2,306.41 545.25 524.30 1,476.31
Price to Earnings (P/E)		 0.00 1.10 0.95 0.63 0.59 0.00 0.00 0.00 0.00 0.00 0.00
Dividend Yield		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings Yield		 0.00% 90.84% 105.13% 157.84% 168.36% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Enterprise Value to Invested Capital (EV/IC)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Revenue (EV/Rev)		 229.16 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 815.37
Enterprise Value to EBITDA (EV/EBITDA)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to EBIT (EV/EBIT)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to NOPAT (EV/NOPAT)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Operating Cash Flow (EV/OCF)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Free Cash Flow (EV/FCFF)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Leverage & Solvency		 - - - - - - - - - - -
Debt to Equity		 0.01 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Long-Term Debt to Equity		 0.01 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Financial Leverage		 -1.14 -1.04 -1.05 -1.04 -1.09 -1.04 -1.05 -1.05 -1.07 -1.07 -1.10
Leverage Ratio		 1.36 1.13 1.17 1.12 1.17 1.08 1.09 1.09 1.11 1.12 1.14
Compound Leverage Factor		 1.36 1.13 1.03 0.99 1.02 0.97 0.95 0.98 1.00 1.03 1.07
Debt to Total Capital		 0.89% 0.09% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Short-Term Debt to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Long-Term Debt to Total Capital		 0.89% 0.09% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Preferred Equity to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Noncontrolling Interests to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Common Equity to Total Capital		 99.11% 99.91% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00%
Debt to EBITDA		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Net Debt to EBITDA		 0.40 3.76 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Long-Term Debt to EBITDA		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Debt to NOPAT		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Net Debt to NOPAT		 0.57 3.74 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Long-Term Debt to NOPAT		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Altman Z-Score		 -20.97 5.73 1.53 0.47 0.24 -1.23 -1.99 -2.58 -4.06 -5.03 -0.39
Noncontrolling Interest Sharing Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Liquidity Ratios		 - - - - - - - - - - -
Current Ratio		 2.18 16.44 11.18 13.68 13.79 12.94 10.25 8.61 6.94 6.33 5.70
Quick Ratio		 1.84 16.10 10.70 13.11 13.41 12.54 9.91 8.40 6.71 6.13 5.52
Cash Flow Metrics		 - - - - - - - - - - -
Free Cash Flow to Firm (FCFF)		 -8.21 16 -16 -17 -21 -20 -12 -8.78 -8.98 -9.39 -10
Operating Cash Flow to CapEx		 0.00% 9,900.00% 0.00% -35,846.77% -119,516.67% -119,553.33% 0.00% -64,881.48% -24,905.63% -78,876.92% -11,820.86%
Free Cash Flow to Firm to Interest Expense		 -391.19 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Operating Cash Flow to Interest Expense		 -502.86 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Operating Cash Flow Less CapEx to Interest Expense		 -502.86 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Efficiency Ratios		 - - - - - - - - - - -
Asset Turnover		 0.01 0.15 0.18 0.21 0.23 0.00 0.00 0.00 0.00 0.00 0.00
Accounts Receivable Turnover		 0.00 126.89 0.00 0.00 0.00 4.73 0.62 0.12 1.86 1.92 6.95
Inventory Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Fixed Asset Turnover		 2.42 128.12 140.93 137.47 146.11 4.54 1.44 0.15 0.54 0.60 0.66
Accounts Payable Turnover		 0.07 0.18 0.15 0.11 0.19 0.00 0.00 0.00 0.00 0.00 0.00
Days Sales Outstanding (DSO)		 0.00 2.88 0.00 0.00 0.00 77.09 588.06 2,977.87 196.44 190.53 52.51
Days Inventory Outstanding (DIO)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Days Payable Outstanding (DPO)		 5,122.81 2,071.60 2,376.99 3,475.17 1,954.34 0.00 0.00 0.00 0.00 0.00 0.00
Cash Conversion Cycle (CCC)		 -5,122.81 -2,068.72 -2,376.99 -3,475.17 -1,954.34 77.09 588.06 2,977.87 196.44 190.53 52.51
Capital & Investment Metrics		 - - - - - - - - - - -
Invested Capital		 -15 -10 -9.10 -5.76 -8.90 -8.69 -11 -14 -16 -17 -18
Invested Capital Turnover		 -0.06 -4.02 -3.92 -6.15 -2.86 -0.12 -0.03 0.00 -0.01 -0.01 -0.01
Increase / (Decrease) in Invested Capital		 -8.20 -4.42 -0.97 -0.43 5.71 1.74 -2.36 -8.30 -7.00 -7.97 -6.98
Enterprise Value (EV)		 139 -115 -102 -135 -126 -132 -119 -94 -93 -69 173
Market Capitalization		 182 169 164 111 107 85 86 95 79 83 313
Book Value per Share		 $0.32 $3.13 $2.92 $2.72 $2.53 $2.35 $2.17 $1.95 $1.74 $1.51 $1.35
Tangible Book Value per Share		 $0.32 $3.13 $2.92 $2.72 $2.53 $2.35 $2.17 $1.95 $1.74 $1.51 $1.35
Total Capital		 28 274 257 240 224 208 193 174 156 136 122
Total Debt		 0.25 0.25 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Long-Term Debt		 0.25 0.25 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Net Debt		 -43 -284 -266 -246 -233 -217 -204 -188 -171 -152 -140
Capital Expenditures (CapEx)		 0.00 0.07 -0.00 0.06 0.01 0.02 -0.00 0.03 0.07 0.03 0.16
Debt-free, Cash-free Net Working Capital (DFCFNWC)		 -15 -11 -9.61 -6.43 -9.58 -9.36 -12 -15 -17 -18 -20
Debt-free Net Working Capital (DFNWC)		 27 273 208 208 196 185 171 144 131 119 112
Net Working Capital (NWC)		 27 273 208 208 196 185 171 144 131 119 112
Net Nonoperating Expense (NNE)		 7.06 -230 4.29 4.42 3.63 5.30 3.59 4.80 4.70 5.52 5.77
Net Nonoperating Obligations (NNO)		 -43 -284 -266 -246 -233 -217 -204 -188 -171 -152 -140
Total Depreciation and Amortization (D&A)		 0.10 0.08 -1.58 -2.03 -1.84 -1.58 -1.41 -1.10 -1.11 -0.77 -0.41
Debt-free, Cash-free Net Working Capital to Revenue		 -2,515.13% -33.94% -28.41% -18.87% -28.45% -825.66% -3,755.56% -36,417.07% -11,677.78% -11,051.57% -9,227.83%
Debt-free Net Working Capital to Revenue		 4,522.86% 827.11% 614.13% 611.05% 582.50% 16,323.81% 52,675.00% 351,456.10% 91,217.36% 74,627.67% 52,867.92%
Net Working Capital to Revenue		 4,522.86% 827.11% 614.13% 611.05% 582.50% 16,323.81% 52,675.00% 351,456.10% 91,217.36% 74,627.67% 52,867.92%
Earnings Adjustments		 - - - - - - - - - - -
Adjusted Basic Earnings per Share		 ($0.27) $2.75 ($0.23) ($0.24) ($0.21) ($0.27) ($0.21) ($0.25) ($0.23) ($0.26) ($0.25)
Adjusted Weighted Average Basic Shares Outstanding		 87.44M 87.63M 87.56M 88.29M 88.58M 88.62M 88.60M 89.26M 89.63M 89.70M 89.70M
Adjusted Diluted Earnings per Share		 ($0.27) $2.75 ($0.26) ($0.24) ($0.21) ($0.27) ($0.21) ($0.25) ($0.23) ($0.26) ($0.25)
Adjusted Weighted Average Diluted Shares Outstanding		 87.44M 87.81M 88.78M 88.29M 88.58M 88.62M 88.60M 89.26M 89.63M 89.70M 89.70M
Adjusted Basic & Diluted Earnings per Share		 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding		 87.62M 88.05M 88.27M 88.58M 88.58M 88.89M 89.21M 89.63M 89.64M 89.94M 93.80M
Normalized Net Operating Profit after Tax (NOPAT)		 -16 12 -17 -17 -15 -19 -15 -17 -16 -17 -17
Normalized NOPAT Margin		 -3,730.20% 35.75% -2,047.89% -5,990.32% -57,475.38% -169,839.09% -364,175.00% 0.00% -12,389.46% -66,750.38% -30,151.58%
Pre Tax Income Margin		 -5,333.64% 741.87% -2,589.31% -7,551.94% -71,446.15% -218,054.55% -454,025.00% 0.00% -16,034.88% -87,996.15% -40,270.18%
Debt Service Ratios		 - - - - - - - - - - -
EBIT to Interest Expense		 -1,116.52 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
NOPAT to Interest Expense		 -781.57 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
EBIT Less CapEx to Interest Expense		 -1,116.52 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
NOPAT Less CapEx to Interest Expense		 -781.57 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Payout Ratios		 - - - - - - - - - - -
Dividend Payout Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Augmented Payout Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%

Key Financial Trends

Chimerix (NASDAQ:CMRX) continues to report operating losses each quarter over the last two years, reflecting its status as a clinical-stage biopharmaceutical company investing heavily in research and development. Operating revenues are minimal, with total revenues ranging from nominal amounts up to $283,000 in early 2023 and $57,000 in Q4 2024, showing no meaningful commercialization as of yet.

Positive factors:

  • Stable share count around 89 million shares outstanding, indicating limited dilution activity during 2023-2024.
  • Consistent generation of positive cash flow from investing activities in recent quarters due to sale/maturity of investments, helping to fund operations.
  • Increasing cash and equivalents from about $15 million in early 2024 to over $23 million in Q3 2024, supporting liquidity.
  • Significant short-term investments ($112 million as of Q3 2024), providing a sizeable liquid asset base.
  • Repayment of debt is minimal, with no onboarding of new long-term debt, indicating manageable leverage.

Neutral factors:

  • Research & development expenses remain very high (around $17-19 million quarterly), consistent with pipeline development efforts but impacting cash burn.
  • Selling, general & admin expenses steady near $5-7 million per quarter, typical for a small cap biotech.
  • Operating losses remain significant around $20-25 million quarterly, reflecting ongoing investment phase.
  • Weighted average shares outstanding mostly stable, showing limited stock issuance but offsetting prior equity raises.

Negative factors:

  • Net losses have not improved materially quarter-over-quarter, with Q4 2024 net loss around $22.95 million.
  • Negative operating income and net income are consistent, with no profitable quarters in the periods analyzed.
  • Negative cash flow from operations ranged from approximately $14 million (Q2 2022) to nearly $20 million (Q3 2024), evidencing ongoing high cash burn.
  • Total liabilities are moderate relative to equity, but retained earnings remain deeply negative reflecting accumulated losses.
  • Recent quarterly revenues remain negligible, indicating continued reliance on capital markets and investments to sustain operations.

In summary, Chimerix remains a high-burn clinical development-stage company with no meaningful revenue generation as of mid-2024. Its strong cash and investment holdings provide a runway for continued R&D spending, but persistent net losses and negative cash flows from operations emphasize the ongoing financial risk until product commercialization or successful partnerships begin to generate revenue.

09/03/25 01:10 PM ETAI Generated. May Contain Errors.

Financials Breakdown Chart

Frequently Asked Questions About Chimerix's Financials

When does Chimerix's financial year end?

According to the most recent income statement we have on file, Chimerix's fiscal year ends in December. Their fiscal year 2024 ended on December 31, 2024.

How has Chimerix's net income changed over the last 10 years?

Chimerix's net income appears to be on a downward trend, with a most recent value of -$88.39 million in 2024, rising from -$59.31 million in 2014. The previous period was -$82.10 million in 2023. Check out Chimerix's forecast to explore projected trends and price targets.

What is Chimerix's operating income?
Chimerix's total operating income in 2024 was -$96.57 million, based on the following breakdown:
  • Total Gross Profit: $212 thousand
  • Total Operating Expenses: $96.78 million
How has Chimerix's revenue changed over the last 10 years?

Over the last 10 years, Chimerix's total revenue changed from $4.04 million in 2014 to $212 thousand in 2024, a change of -94.8%.

How much debt does Chimerix have?

Chimerix's total liabilities were at $24.33 million at the end of 2024, a 23.2% increase from 2023, and a 41.1% increase since 2014.

How much cash does Chimerix have?

In the past 10 years, Chimerix's cash and equivalents has ranged from $15.40 million in 2021 to $128.46 million in 2014, and is currently $31.05 million as of their latest financial filing in 2024.

How has Chimerix's book value per share changed over the last 10 years?

Over the last 10 years, Chimerix's book value per share changed from 7.53 in 2014 to 1.35 in 2024, a change of -82.0%.


Related Companies

This page (NASDAQ:CMRX) was last updated on 9/3/2025 by MarketBeat.com Staff
From Our Partners
How “Trump’s New Dollar” Could Impact Your Wealth
President Trump just signed a game-changing law… That could soon upgrade the U.S. dollar in your checking a...
Brownstone Research | Sponsoredtc pixel
Forget Tesla — This Tiny AI Stock Is Musk’s Real Play
While Wall Street focused on Tesla’s earnings, Elon Musk was quietly building a supercomputer so powerful it c...
Behind the Markets | Sponsoredtc pixel
What's the Best Way to Lower RMD Taxes?
Turning 73 triggers a key IRS rule: you must begin taking required minimum distributions (RMDs) from certain r...
SmartAsset | Sponsoredtc pixel
What Steve Bannon revealed about Trump’s gold play
A Trump advisor just said 3 words that could reset the dollar. It’s a gold move nobody saw coming—and your ...
Reagan Gold Group | Sponsoredtc pixel
Market Panic: Trump Just Dropped a Bomb on Your Stocks
tock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...
American Alternative | Sponsoredtc pixel
Warren Buffett Issues Cryptic Warning on U.S. Dollar
Imagine a bull market so powerful, every single investor became a millionaire. Not by finding the next NVIDIA ...
Banyan Hill Publishing | Sponsoredtc pixel
Google did what!?!?
A new technology has sparked a modern-day gold rush in Silicon Valley. OpenAI’s Sam Altman invested $375M. Bil...
Stansberry Research | Sponsoredtc pixel
Out of 18,347 Cryptocurrencies... This is the ONLY One
The $365M annual revenue crypto play While Bitcoin generates zero operational revenue, one DeFi protocol qu...
Crypto 101 Media | Sponsoredtc pixel